Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Lajos Géczi et al.|The Lancet Oncology|2021Cited by 645
Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancerTeppei Nishii, Munetaka Masuda, Tomoyuki Yokose et al.|BMC Cancer|2014Cited by 28